Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 7,077 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Completed Not applicable Interventional

Outcomes of Triaged Family Care in Advanced Cancer

NCT00709176
View directory record Official record
Conditions
Advanced Cancer
Interventions
Brief FOCUS Program, Extensive FOCUS Program
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
5
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 28, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

NCT03451162
View directory record Official record
Conditions
Breast Cancer
Interventions
DHES0815A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 28, 2026, 10:27 AM EDT
Completed No phase listed Observational

Registry of Mastectomy for Breast Cancer Risk Reduction

NCT00555503
View directory record Official record
Conditions
Quality of Life, Mastectomy, Breast Neoplasms, Genetic Predisposition to Disease, Adjustment Disorder
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 28, 2026, 10:27 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer

NCT04095689
View directory record Official record
Conditions
Triple Negative Breast Cancer, Anthracycline-refractory TNBC
Interventions
Docetaxel, Pembrolizumab, IL-12 gene therapy
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 28, 2026, 10:27 AM EDT
Completed Not applicable Interventional

Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors

NCT00335491
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Fatigue, Lung Cancer, Lymphoma, Ovarian Cancer, Prostate Cancer
Interventions
exercise intervention, complementary or alternative medicine procedure, fatigue assessment and management, physical therapy
Behavioral · Procedure
Lead sponsor
University of Utah
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 30, 2011 · Synced Oct 28, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

NCT00479674
View directory record Official record
Conditions
Breast Cancer
Interventions
Abraxane, Bevacizumab, Carboplatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
4
States / cities
Charlotte, North Carolina • Concord, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 28, 2026, 10:27 AM EDT
Not listed Not applicable Interventional

Dermacell ADM Without Basement Membrane

NCT03667560
View directory record Official record
Conditions
Breast Cancer
Interventions
Dermacell ADM without basement membrane, FlexHD
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 28, 2026, 10:27 AM EDT
Withdrawn No phase listed Observational

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

NCT00873808
View directory record Official record
Conditions
Breast Cancer
Interventions
clodronate disodium, demeclocycline hydrochloride, ibandronate sodium, tetracycline hydrochloride, zoledronic acid, laboratory biomarker analysis, adjuvant therapy, computed tomography, dual x-ray absorptiometry
Drug · Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Oct 28, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)

NCT00978250
View directory record Official record
Conditions
Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
Interventions
5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
4
States / cities
Davis, California • Duarte, California • South Pasadena, California + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 28, 2026, 10:27 AM EDT
Terminated Phase 1 Interventional Results available

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

NCT03685591
View directory record Official record
Conditions
Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms
Interventions
PF-06952229, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 28, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutrition, Exercise, and Breast Cancer Survivorship

NCT01151488
View directory record Official record
Conditions
Breast Cancer Survivorship, Sarcopenia
Interventions
Resistance Training
Other
Lead sponsor
Baltimore VA Medical Center
Federal
Eligibility
45 Years to 80 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 28, 2026, 10:27 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

NCT00004125
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, docetaxel, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2016
U.S. locations
48
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 28, 2026, 10:27 AM EDT
Withdrawn No phase listed Observational

Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer

NCT00329017
View directory record Official record
Conditions
Breast Cancer
Interventions
Fine needle aspiration
Procedure
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 28, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Soy Isoflavones and Breast Cancer Risk Reduction

NCT00204490
View directory record Official record
Conditions
Breast Cancer
Interventions
isoflavones, carbohydrate
Dietary Supplement
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
30 Years to 42 Years · Female only
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 28, 2026, 10:27 AM EDT
Completed Not applicable Interventional

Acupuncture for Aromatase Inhibitor Induced Joint Pain

NCT00826397
View directory record Official record
Conditions
Breast Cancer
Interventions
Acupuncture, Sham Acupuncture
Procedure
Lead sponsor
Columbia University
Other
Eligibility
45 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 28, 2026, 10:27 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer

NCT07374796
View directory record Official record
Conditions
Breast Cancer (Locally Advanced or Metastatic), Healthy Volunteers (HV), Unhealthy Volunteers, Breast Cancer Screening
Interventions
Epigenetic Assay
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2033
U.S. locations
1
States / cities
Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 28, 2026, 10:27 AM EDT
Completed No phase listed Observational

Extended Follow-up of Columbia, MO Serum Bank Participants

NCT00340210
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
6,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 28, 2026, 10:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy

NCT01313117
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Alpha lipoic acid
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 28, 2026, 10:27 AM EDT
Completed No phase listed Observational

Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Companion Study

NCT04361240
View directory record Official record
Conditions
Breast Cancer, Cardiotoxicity
Interventions
Proton vs Photon Radiation
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Warrenville, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 28, 2026, 10:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

NCT02111850
View directory record Official record
Conditions
Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma, Breast Cancer
Interventions
Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL), Cyclophosphamide, Fludarabine, Aldesleukin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 28, 2026, 10:27 AM EDT
Completed No phase listed Observational

Investigation of Diagnostic Improvement Gained Through Optimization of MR Methods for Breast Cancer Detection

NCT02411760
View directory record Official record
Conditions
Breast Neoplasms
Interventions
3 Tesla Magnetic Resonance Imaging
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 28, 2026, 10:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

NCT06374459
View directory record Official record
Conditions
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Interventions
Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Westwood, Kansas • Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 10:27 AM EDT
Completed Not applicable Interventional

In Vitro Detection of Tissue Abnormality

NCT01209182
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Testing a new device (LS BioPath TOUCH) on excised tissue
Device
Lead sponsor
LS BioPath
Industry
Eligibility
25 Years to 80 Years · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 28, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

NCT03007979
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
Interventions
Palbociclib, Letrozole, Fulvestrant, Optional research biopsy, Goserelin, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional)
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
St Louis, Missouri • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 28, 2026, 10:27 AM EDT